Pharmaceuticals

Non-Alcoholic Steatohepatitis Treatment Market Expansion Outlook: $13.57 Billion by 2029 Forecast

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Non-Alcoholic Steatohepatitis Treatment Market Between 2025 And 2029?

The non-alcoholic steatohepatitis treatment market has experienced rapid expansion in recent years. Its valuation is set to climb from $2.6 billion in 2024 to $3.57 billion in 2025, progressing at a strong compound annual growth rate of 37.5%. Key contributors to this historical growth include the escalating incidence of NASH, heightened awareness and diagnostic rates, widespread lifestyle modifications and the obesity crisis, ongoing clinical research, improvements in healthcare infrastructure and access, and positive regulatory backing coupled with clinical trials.

The non-alcoholic steatohepatitis treatment market size is projected for substantial expansion in the coming years. This market is anticipated to reach $13.57 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 39.6%. This projected increase during the forecast period stems from progress in drug development, greater awareness of the disease, an increase in its prevalence and associated risk factors, and a move towards personalized medicine. Key developments expected in this timeframe encompass a patient-centric approach, technological advancements, the emergence of targeted therapies, an evolving regulatory landscape, and breakthroughs in research.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

What Are The Top Growth Drivers Impacting The Non-Alcoholic Steatohepatitis Treatment Market Outlook?

The expansion of the non-alcoholic steatohepatitis treatment market is being driven by a rise in the incidence of insulin resistance. This condition develops when muscle, fat, and liver cells fail to respond sufficiently to insulin, impeding their ability to absorb glucose from the bloodstream, which leads to elevated blood sugar levels. Factors contributing to this include an unhealthy lifestyle, high sugar intake, and genetic predisposition. The prevalence of insulin resistance has escalated due to the growing cases of diabetes and various liver problems, both of which are addressed by non-alcoholic steatohepatitis treatment. For example, a January 2022 report by the International Diabetes Federation, a Belgium-based global diabetes community, indicated that diabetes impacts 537 million individuals (20-79 years old), representing one in every ten people, with projections showing an increase to 643 million by 2030 and 783 million by 2045. Additionally, in January 2024, the American Cancer Society, a US-based nonprofit cancer advocacy organization, forecasted that new liver cancer cases would total 41,630 in 2024, an increase from 41,210 in 2023. Consequently, the rising prevalence of insulin resistance, stemming from numerous liver and diabetes conditions, is set to propel the non-alcoholic steatohepatitis treatment market.

What Are The Different Segment Classifications Within The Non-Alcoholic Steatohepatitis Treatment Market?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

What Trends Are Redefining The Non-Alcoholic Steatohepatitis Treatment Market Dynamics?

The advancement of non-alcoholic steatohepatitis (NASH) drugs represents a key trend growing in popularity within the non-alcoholic steatohepatitis treatment market. Numerous companies are channeling investments into creating innovative drugs for treating liver diseases, focusing on reducing their side effects. For instance, in May 2022, Pfizer Inc., an American pharmaceutical and biotechnology company, was granted fast-track designation by the U.S. Food and Drug Administration (FDA) to accelerate the development of its non-alcoholic steatohepatitis (NASH) drugs, specifically ervogastat and clesacostat. The Fast Track initiative is tailored for Pfizer’s experimental combination therapy aimed at non-alcoholic steatohepatitis (NASH) with liver fibrosis, which includes ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Who Are The Key Multinational Companies Dominating The Non-Alcoholic Steatohepatitis Treatment Market?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Regional Growth Trends Are Shaping The Non-Alcoholic Steatohepatitis Treatment Market Outlook?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Non-Alcoholic Steatohepatitis Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2025, By The Business Research Company

Nutritional Analysis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nutritional-analysis-global-market-report

Probiotics Dietary Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/probiotics-dietary-supplements-global-market-report

Protein Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-supplements-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795